SCHEMBL2120646

SCHEMBL2120646

CCCCCCCC/C=C\CCCCCCCCOC(=O)C(CC(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+]

nearest known ligand 0.49

Known targets — ChEMBL curated mechanism

ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 7/20 0.47
FAAH O00519 3/20 0.44
SLC6A5 Q9Y345 1/20 0.44
EPHX2 P34913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29391237 0.93 FABP3 (0.43) FABP3SLC6A5EPHX2
SCHEMBL4941637 0.92 TSHR (0.45) EPHX2
SCHEMBL5982864 0.92 TSHR (0.45) EPHX2
SCHEMBL11203648 0.92 TSHR (0.45) EPHX2
SCHEMBL4809983 0.92 TSHR (0.45) EPHX2
SCHEMBL401361 0.92 TSHR (0.45) EPHX2
SCHEMBL2729134 0.92 TSHR (0.45) EPHX2
SCHEMBL208566 0.92 TSHR (0.45) EPHX2
SCHEMBL158736 0.92 TSHR (0.45) EPHX2
SCHEMBL23064683 0.91 FABP3 (0.48) FABP3FAAHSLC6A5EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080299065-A1 COMPOSITION CONTAINING SULFONIC ACID AND/OR SULFURIC ACID COMPOUND L'OREAL (FR) 2008-12-04 US claimed
US-20080188574-A1 LIghtweight, clean feel; long lasting, sweat resistant sunscreen cosmetics; preparation with high speed bead mill; hydrophobic treatment SUNJIN CHEMICAL CO., LTD. (KR) 2008-08-07 US claimed
EP-1920799-A1 Cosmetic composition comprising a derivative of sulfonic acid or a derivative of sulfuric acid L'Oréal (FR) 2008-05-14 EP claimed
US-12629327-B2 Keratin-based hair straightening formulations, methods and systems BEAUTY BIOLABS LLC (US) 2026-05-19 US disclosed
CN-119997951-A Method for preventing, alleviating and/or treating PTGS 2-induced skin disorders and related dysfunctions 西姆莱斯股份公司 2025-05-13 CN disclosed
CN-114728092-B Edge block with improved odor performance 西姆莱斯股份公司 2025-02-28 CN disclosed
CN-119486725-A (2E) Mixtures and uses of (E) -3- (1, 3-benzodioxol-5-yl) -N-phenyl-N- (tetrahydro-3-furanyl) -2-propenamide 西姆莱斯有限公司 2025-02-18 CN disclosed
US-20240409779-A1 MOISTURE CURABLE ADHESIVE COMPOSITION ARKEMA FRANCE (FR) 2024-12-12 US disclosed
US-20240390258-A1 FOAMING COMPOSITION L'OREAL (FR) 2024-11-28 US disclosed
CN-118922168-A Sun cream additive 西姆莱斯股份公司 2024-11-08 CN disclosed
CN-118891030-A Hair care compositions 西姆莱斯股份公司 2024-11-01 CN disclosed
US-20090165812-A1 HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS LIQUID KERATIN, INC. (CA) 2009-07-02 US disclosed
US-20090104430-A1 LATHER-FORMING TISSUE PAPER PRODUCT SCA HYGIENE PRODUCTS AB (SE) 2009-04-23 US disclosed
US-20090081755-A1 FRAGRANT CONSUMER PRODUCTS COMPRISING OXIDIZING AGENTS HENKEL AG & CO. KG A (DE) 2009-03-26 US disclosed
WO-2009035970-A1 HAIR STRAIGHTENING FORMULATIONS, METHODS AND SYSTEMS RESNICK LIONEL (US) 2009-03-19 WO disclosed
EP-2002058-A1 LATHER-FORMING TISSUE PAPER PRODUCT SCA Hygiene Products GmbH (DE) 2008-12-17 EP disclosed
US-20080299065-A1 COMPOSITION CONTAINING SULFONIC ACID AND/OR SULFURIC ACID COMPOUND L'OREAL (FR) 2008-12-04 US disclosed
US-20080188574-A1 LIghtweight, clean feel; long lasting, sweat resistant sunscreen cosmetics; preparation with high speed bead mill; hydrophobic treatment SUNJIN CHEMICAL CO., LTD. (KR) 2008-08-07 US disclosed
EP-1920799-A1 Cosmetic composition comprising a derivative of sulfonic acid or a derivative of sulfuric acid L'Oréal (FR) 2008-05-14 EP disclosed
WO-2007112916-A1 LATHER-FORMING TISSUE PAPER PRODUCT SCA HYGIENE PRODUCTS GMBH (DE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629327-B2 Keratin-based hair straightening formulations, methods and systems KRT18, HCN4, COL14A1 FABP3 3240/4885FAAH 3621/4885SLC6A5 443/4885
US-20240390258-A1 FOAMING COMPOSITION SGMS1, SGMS2, SMURF1 FABP3 440/4885FAAH 164/4885SLC6A5 1484/4885
US-20080299065-A1 COMPOSITION CONTAINING SULFONIC ACID AND/OR SULFURIC ACID COMPOUND STS, MPST, TST FABP3 634/4885FAAH 342/4885SLC6A5 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.